Benefits
BPH Symptom Improvement
Plasys300 designed to improve symptoms of benign prostatic hyperplasia — urinary frequency, urgency, weak flow, nocturia, incomplete emptying.
Urinary Flow Support
Targeted at the urinary symptoms of BPH which result from prostate enlargement compressing urethra.
Prostate Health for Aging Men
BPH affects 50%+ of men by age 50, 80%+ by age 80; Plasys300 positioned for this large aging male demographic.
Standardized Botanical Formulation
Pharmactive standardization ensures consistent active compound delivery for reproducible BPH symptom relief.
Alternative or Adjunct to BPH Medications
Useful for men: avoiding prescription medications, with mild-moderate symptoms, or as adjunct to alpha-blockers/5α-reductase inhibitors.
Mechanism of action
Prostate-Specific Activity
Plasys300 designed for prostate tissue effects per Pharmactive research; mechanism includes addressing BPH symptom drivers.
Urinary Symptom Pathway Effects
Mechanism likely involves prostate tissue, bladder/urethra effects, possible inflammatory pathway modulation common in BPH science.
Standardized Active Compound Delivery
Pharmactive standardization for clinically reproducible effects.
Clinical trials
Pharmactive clinical trials of Plasys300 for BPH symptom management.
Men with BPH symptoms.
Improvements in BPH-related urinary symptoms and quality of life.
About this ingredient
PLASYS300® is a BOTANICAL INGREDIENT FOR BENIGN PROSTATIC HYPERPLASIA (BPH) developed by PHARMACTIVE BIOTECH PRODUCTS (Spain). POSITIONING: 'improves symptoms of benign prostatic hyperplasia.' BPH BACKGROUND: progressive enlargement of prostate gland with age; symptoms include urinary frequency, urgency, weak stream, nocturia (nighttime urination), incomplete emptying, hesitancy.
EVIDENCE-BASED USES: (1) BPH SYMPTOM IMPROVEMENT; (2) Urinary flow support; (3) Prostate health for aging men; (4) Alternative or adjunct to BPH medications.
CRITICAL CAUTIONS: (1) MEDICAL EVALUATION FIRST — urinary symptoms warrant medical evaluation to rule out: prostate cancer, urinary retention, kidney impact, urinary tract infection; Plasys300 is for ESTABLISHED BPH adjunctive care, not bypass medical evaluation; (2) PROSTATE CANCER — symptoms can overlap with BPH; PSA testing and digital rectal exam appropriate before symptom-only treatment; (3) MEDICATION INTERACTIONS — alpha-blockers (tamsulosin, alfuzosin, doxazosin), 5α-reductase inhibitors (finasteride, dutasteride) are standard BPH medications; consult prescriber; (4) DOSE — 300 mg suggested by product name per Pharmactive specification; (5) DURATION — BPH symptom effects typically build over 8-12 weeks; not immediate; (6) PLASYS300 vs SAW PALMETTO vs BETA-SITOSTEROL vs AGEPROST (Saanroo) — multiple natural prostate support options; choice based on specific clinical context; (7) WATCHFUL WAITING — early BPH may not require treatment; lifestyle measures (limit fluids before bed, double voiding, alcohol/caffeine moderation) foundational; Plasys300 may be adjunct; (8) ACUTE URINARY RETENTION — emergency requiring catheterization and possible surgery; not addressed by supplements; (9) BRAND VERIFICATION — Plasys300® is Pharmactive trademark; specific clinical evidence on this proprietary formulation; (10) HEALTHY AGING APPROACH — comprehensive aging male health includes cardiovascular, metabolic, exercise, weight, sexual health, prostate health; Plasys300 one component; (11) ELDERLY POPULATIONS — most relevant target demographic; ensure compatibility with other medications common in older men; (12) PROSTATE CANCER PREVENTION — BPH does NOT necessarily lead to prostate cancer; Plasys300 for symptom management not cancer prevention; (13) For COMPREHENSIVE PROSTATE HEALTH PROTOCOLS — comprehensive approach: medical screening, lifestyle, medications when warranted, Plasys300 as supplement adjunct.